Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03960177
Recruitment Status : Recruiting
First Posted : May 22, 2019
Last Update Posted : November 16, 2021
Sponsor:
Collaborators:
BTG International Inc.
Oregon Health and Science University
Information provided by (Responsible Party):
Lara Davis, OHSU Knight Cancer Institute

Brief Summary:
This early phase I trial studies how well glucarpidase works in reducing toxicity in patients with osteosarcoma receiving high dose methotrexate treatment. Glucarpidase may reduce the levels of methotrexate in patients' blood and lead to shorter hospitalizations and a reduction in toxicities.

Condition or disease Intervention/treatment Phase
Osteosarcoma Drug: Glucarpidase Other: Quality-of-Life Assessment Early Phase 1

Detailed Description:

PRIMARY OBJECTIVE:

I. To determine the rate of completion of 4 planned high dose methotrexate (HDMTX) doses when glucarpidase is administered after each dose.

SECONDARY OBJECTIVES:

I. To assess the length of hospital stay (LOS) associated with methotrexate (MTX) clearance following administration of glucarpidase 24 hours after HDMTX.

II. To assess the LOS associated with all causes following administration of glucarpidase 24 hours after HDMTX.

III. To assess the impact of glucarpidase administration on HDMTX efficacy. IV. To assess the safety and tolerability of 4 doses of HDMTX administered with glucarpidase in an adult osteosarcoma population.

V. To assess the efficacy of glucarpidase flat dose of 1,000 units.

OUTLINE:

Patients receive standard of care HDMTX intravenously (IV) over 4 hours on day 1 of weeks 4, 5, 9, and 10. After 24 and 48 hours after the start of each HDMTX infusion, patients also receive glucarpidase IV over 5 minutes in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 32 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Multi-Institutional Pilot Study to Assess the Use of Glucarpidase in Adult Patients With Osteosarcoma Receiving High-Dose Methotrexate
Actual Study Start Date : March 27, 2019
Estimated Primary Completion Date : October 1, 2022
Estimated Study Completion Date : October 1, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Treatment (glucarpidase)
Patients receive standard of care HDMTX IV over 4 hours on day 1 of weeks 4, 5, 9, and 10. After 24 hours after the start of each HDMTX infusion, patients also receive glucarpidase IV over 5 minutes in the absence of disease progression or unacceptable toxicity.
Drug: Glucarpidase
Given IV
Other Names:
  • Acetylaspartylglutamate Dipeptidase
  • Carboxypeptidase G2
  • carboxypeptidase-G2
  • CPDG2
  • CPG2
  • Poly(gamma-glutamic Acid) Endohydrolase
  • Pteroylpolygammaglutamyl Hydrolase
  • Voraxaze

Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment




Primary Outcome Measures :
  1. Proportion of subjects completing 4 planned doses of high dose methotrexate (HDMTX) [ Time Frame: Time from first dose of HDMTX to time of last dose of HDMTX (week 10) ]
    Will be estimated with an exact 95% confidence interval (CI).


Secondary Outcome Measures :
  1. Length of hospital stay (LOS) for methotrexate (MTX) clearance [ Time Frame: Time of start of MTX administration to time of MTX =< 0.1uM sample collection for each planned MTX infusion (up to 15 days) ]
  2. LOS for all causes (excluding MTX-related AEs) [ Time Frame: Date of admission for each planned MTX infusion to date of discharge for each planned MTX infusion (up to 15 days) ]
  3. Length of hospital stay (LOS) for methotrexate (MTX)-related adverse events (AEs) [ Time Frame: Date of admission for each planned MTX infusion to date of discharge for each planned MTX infusion (up to 15 days) ]
  4. Percent treatment effect at resection [ Time Frame: From start of surgery until end of surgery ]
    Defined as an admixture of degenerating wispy osteoid matrix with empty lacunae, necrotic ghost cells, and edematous stroma with loose fibrous tissue. Dense fibrosis or hyalinization or sheets of sclerotic acellular osteoid may also be present. These features are quantified by estimating the percentage of each parameter in each tumor slide and calculating the mean based on the total number of tumor slides examined. The percentage of tumor necrosis or treatment effect will be recorded from each participant's surgical pathology report.

  5. Incidence of glucarpidase hypersensitivity [ Time Frame: From first dose of glucarpidase until 30 days after last dose of glucarpidase ]
    Will be assessed according to Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0. Will be determined for participants that received at least 1 dose of glucarpidase following an HDMTX infusion. The 95% CI will be reported with the point estimate of toxicity rate.

  6. Incidence of glucarpidase neutralizing antibodies [ Time Frame: From first dose of glucarpidase to 30 days after last dose of glucarpidase ]
    Will be determined for participants that received at least 1 dose of glucarpidase following an HDMTX infusion. The 95% CI will be reported with the point estimate of toxicity rate.

  7. Incidence and severity of MTX-related toxicities [ Time Frame: From start of first planned MTX infusion to 30 days after last dose of MTX ]
    Will be assessed according to CTCAE v 5.0. Will be determined for participants that received at least 1 dose of glucarpidase following an HDMTX infusion. The 95% CI will be reported with the point estimate of toxicity rate.

  8. Incidence and severity of glucarpidase toxicities [ Time Frame: From first dose of glucarpidase to 30 days after last dose of glucarpidase ]
    Will be assessed according to CTCAE v 5.0. Will be determined for participants that received at least 1 dose of glucarpidase following an HDMTX infusion. The 95% CI will be reported with the point estimate of toxicity rate.

  9. MTX and DAMPA serum concentration (umol/L) at 4, 24, 24.5, 36, 48 and every 24 hours after the start of MTX infusion [ Time Frame: From start of each planned MTX infusion to time when MTX =< 0.1 uM (for each planned MTX infusion) (up to 15 days) ]
  10. Proportion of glucarpidase doses (flat dose) that result in MTX serum concentration reduction of >= 97% from hour 24 to hour 24.5 [ Time Frame: From first dose of glucarpidase to end of study treatment (week 10) ]
    Will be presented along with 95% confidence intervals. Summary statistics will be reported on the efficacy analysis set with sub-analyses stratified by glucarpidase dose.

  11. Proportion of glucarpidase doses (flat dose) that result in 48 hour serum MTX level < 1 uM [ Time Frame: From first dose of glucarpidase to end of study treatment (week 10) ]
    Will be presented along with 95% confidence intervals. Summary statistics will be reported on the efficacy analysis set with sub-analyses stratified by glucarpidase dose.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All races and ethnic groups will be eligible

    • A minimum of 6 individuals aged >= 40 years will be enrolled. These participants are considered high-risk.
  • Eastern Cooperative Oncology Group (ECOG) performance score 0-2.
  • Participants must have pathologically confirmed diagnosis of osteosarcoma. Participants must be newly diagnosed and previously untreated, although initiation of doxorubicin/cisplatin prior to enrollment is permitted.
  • Participants must have a recommended treatment plan for their osteosarcoma that includes planned MTX treatment at 8-12 g/m^2.
  • Absolute neutrophil count (ANC) >= 1,000/mm^3 (or >= 1.0 x 10^9/L).
  • Platelet count 75,000/mm^3 (or >= 75 x 10^9/L).
  • Hemoglobin >= 8 g/dL.
  • Serum creatinine =< 1.5 x the upper limit of normal (ULN), or glomerular filtration rate (GFR) >= 60 ml/min/1.73 m^2 as calculated by the Modification of Diet in Renal Disease (MDRD) formula.
  • Total serum bilirubin =< 2 x ULN.
  • Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) =< 2.5 x ULN.
  • Participants must be willing to use appropriate contraception for the duration of study treatment and four months after completing HDMTX therapy.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Malignant disease, other than those being treated in this study. Exceptions to this exclusion include the following:

    • Malignancies that were treated curatively and have not recurred within 2 years after completion of treatment;
    • Completely resected basal cell and squamous cell skin cancers;
    • Any malignancy considered to be indolent and that has never required therapy;
    • Completely resected carcinoma in situ of any type.
  • Participants with rapidly progressive disease or organ dysfunction that would prevent them from receiving planned HDMTX treatment regimen.
  • Previous MTX treatment at doses >= 3 g/m^2.
  • Previous treatment with glucarpidase.
  • Known clinically significant liver disease defined as ongoing drug-induced liver injury, chronic active hepatitis C (HCV), chronic active hepatitis B (HBV), alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, portal hypertension, or history of autoimmune hepatitis. Patients who have completed curative therapy for HCV are eligible. Patients with known history of human immunodeficiency virus (HIV) infection are eligible.
  • Participants with a history of hypersensitivity reactions to study agent or its excipients.
  • Participants with a history of hypersensitivity to Escherichia (E.)coli-derived proteins.
  • Participants with large pleural or ascitic fluid collection.
  • Participant is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.
  • Uncontrolled intercurrent illness, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
  • Unable or unwilling to discontinue use of agents that interact significantly with methotrexate metabolism or excretion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03960177


Locations
Layout table for location information
United States, Florida
Mayo Clinic in Florida Recruiting
Jacksonville, Florida, United States, 32224-9980
Contact: Steven Attia    904-953-7290    Attia.Steven@mayo.edu   
Principal Investigator: Steven Attia         
United States, Minnesota
Mayo Clinic in Rochester Recruiting
Rochester, Minnesota, United States, 55905
Contact: Brittany Siontis    507-293-0585    Siontis.Brittany@mayo.edu   
Principal Investigator: Brittany Siontis         
United States, New York
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Katherine A. Thornton    646-888-6952    thorntk1@mskcc.org   
Principal Investigator: Katherine A. Thornton         
United States, Oregon
OHSU Knight Cancer Institute Recruiting
Portland, Oregon, United States, 97239
Contact: Lara E. Davis    503-494-8423    davisla@ohsu.edu   
Principal Investigator: Lara E. Davis         
United States, Pennsylvania
University of Pennsylvania/Abramson Cancer Center Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Robert Maki, MD PhD    215-615-1594    PAhemoncResearch@uphs.upenn.edu   
Principal Investigator: Robert Maki, MD PhD         
Sponsors and Collaborators
OHSU Knight Cancer Institute
BTG International Inc.
Oregon Health and Science University
Investigators
Layout table for investigator information
Principal Investigator: Lara E Davis OHSU Knight Cancer Institute
Layout table for additonal information
Responsible Party: Lara Davis, Principal Investigator, OHSU Knight Cancer Institute
ClinicalTrials.gov Identifier: NCT03960177    
Other Study ID Numbers: STUDY00019380
NCI-2019-02257 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
STUDY00019380 ( Other Identifier: OHSU Knight Cancer Institute )
First Posted: May 22, 2019    Key Record Dates
Last Update Posted: November 16, 2021
Last Verified: November 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteosarcoma
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Sarcoma